Isembyld (apitegromab)

The first SMA treatment that targets muscle rather than motor neurons. Isembyld is an add-on given by infusion every 4 weeks to patients 2 and older who are already taking Spinraza or Evrysdi, and it works by blocking myostatin, a protein that limits muscle growth.

Every approved SMA therapy before this one worked on the genetic root of the disease, raising levels of the SMN protein that motor neurons need to survive. None of them acted on muscle that had already wasted away. Apitegromab takes the other route. The body produces a protein called myostatin that limits how much muscle it builds, and myostatin is made first in inactive precursor forms, called promyostatin and latent myostatin, which have to be switched on before they do anything. Apitegromab binds those precursor forms and prevents the activation step, so the brake is never applied. Targeting the precursors rather than the finished protein is what distinguishes it from earlier myostatin drugs that failed, because it leaves closely related proteins such as activin A alone. Because it acts on muscle rather than on the SMN gene, it is designed to be layered on top of an SMN-targeted drug rather than to replace one.

Fractures are the one risk that carries a dedicated warning in the label, occurring in 9% of patients on the recommended dose versus 2% on placebo, and they can happen with or without a fall. The label tells prescribers to use caution in anyone with a history of low bone density or multiple fractures and to weigh whether to continue treatment if a fracture occurs. The concern is grounded in animal work: rats given apitegromab developed hip damage, including fissures and loss of the femoral head, at every dose tested, and no dose free of bone effects was identified. The most common reactions reported in at least 20% of treated patients were upper respiratory tract infections (66%), vomiting (30%), cough (28%), other viral infections (26%), headache (23%), gastroenteritis (23%), pharyngitis (21%) and hypersensitivity (21%). Diarrhea and infusion site reactions each occurred in patients on the drug and in none on placebo. Serious pneumonia occurred in 3 treated patients and no placebo patients. Blood creatine phosphokinase rose in 28% of treated patients versus 12% on placebo, usually without symptoms. Animal studies also showed effects on fertility and on offspring development at every dose tested, with no no-effect dose identified, and the label warns the drug may cause fetal harm; there is no human data on either question. Anti-drug antibodies were rare, appearing in 1 of 128 patients.

Given as an intravenous infusion of 10 mg/kg once every 4 weeks, delivered over roughly 60 to 120 minutes at a rate no faster than 150 mL per hour. It is supplied as a 150 mg/3 mL single-dose vial and must be diluted in saline by a healthcare professional before use. Scholar Rock says infusions can be arranged at a hospital, an infusion center, or at home depending on eligibility. A 20 mg/kg dose was also tested in the pivotal trial but is not recommended, because it produced no additional benefit. If a dose is missed, it can be given as soon as possible with the schedule restarting from that date, or skipped to stay on the original schedule. Drug levels reach steady state after about 16 to 20 weeks, and the antibody has a half-life of roughly 31 days.

Yes, Apitegromab (Isembyld) is FDA approved (2026) for the treatment of Spinal Muscular Atrophy.

Isembyld (apitegromab) is approved for spinal muscular atrophy in adults and children 2 years of age and older who are currently receiving an SMN2-targeted treatment, meaning Spinraza (nusinersen) or Evrysdi (risdiplam). It is an add-on therapy and is not approved to be taken on its own. The FDA approved it on September 11, 2026.

Those three drugs all raise levels of the SMN protein that motor neurons need to survive, either by modifying how the SMN2 gene is read or by delivering a working SMN1 gene. Isembyld does not touch the SMN pathway at all. It blocks myostatin, a protein that limits muscle growth, making it the first SMA treatment aimed at muscle rather than motor neurons. That is also why it is taken alongside one of the others rather than instead of one.

Not if Zolgensma is your only SMA treatment. Isembyld requires that a patient be currently receiving an SMN2-targeted treatment, and Zolgensma is a one-time SMN1 gene replacement rather than an ongoing SMN2-targeted drug. A patient who had Zolgensma and is now also taking Spinraza or Evrysdi meets the label's wording, because the label only requires a current SMN2-targeted treatment and does not exclude past gene therapy. The SAPPHIRE trial did exclude anyone who had previously received Zolgensma, so there is no trial data for this group, which is worth discussing with a neuromuscular specialist.

In the SAPPHIRE trial, patients aged 2 to 12 on the recommended dose gained 1.0 point on the 66-point HFMSE motor scale over a year while patients on placebo lost 1.2, a difference of 2.2 points with a confidence interval of 0.49 to 3.95. A gain of 3 points or more was reached by 34.2% of treated patients versus 13.5% on placebo. The comparison matters as much as the size, because the placebo group was also on an SMN drug and still declined.

There is no direct evidence either way. The approved label does not restrict use based on walking status, so ambulatory patients qualify, but every patient enrolled in SAPPHIRE was nonambulatory at baseline with Type 2 or Type 3 SMA. An ambulatory patient is therefore a reasonable candidate under the label and also a patient type that was not studied, which is worth raising directly with a neuromuscular specialist.

Fractures occurred in 9% of patients on the recommended dose compared with 2% on placebo, and they can happen with or without a fall. This is the only warning in the label, and prescribers are told to use caution in patients with a history of low bone density or multiple fractures and to weigh whether to continue if a fracture occurs. Animal studies found hip damage at every dose tested with no safe dose identified, which suggests the signal follows the drug rather than chance. People with SMA already have elevated fracture risk from reduced weight-bearing, so bone health is worth discussing before starting.

It is an intravenous infusion of 10 mg/kg once every 4 weeks, running roughly 60 to 120 minutes. Scholar Rock says infusions can be given at a hospital, an infusion center, or at home depending on eligibility. This is in addition to the schedule of whatever SMN-targeted therapy the patient is already taking.

The four-letter suffix is assigned by the FDA to biologic drugs so they can be distinguished from future biosimilar versions of the same molecule. It carries no clinical meaning and says nothing about how the drug works. Apitegromab is the generic name, Isembyld is the brand name, and SRK-015 was the development code used during trials.